--- title: "Quantum Biopharma (QNTM) news: delisting" url: "https://aibio.space/companies/quantum-biopharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "QNTM delisting news: Quantum BioPharma applies to delist Class B shares from the CSE. Quantum Biopharma Ltd. (NASDAQ: QNTM), Canada." --- QNTM Quantum Biopharma Ltd. NASDAQ · Canada # Quantum Biopharma (QNTM) news QNTM delisting news Debt Financing · 2026-09-17 ## [Quantum BioPharma closes fourth debenture tranche of $100,000, cancels director warrants](https://aibio.space/news/quantum-biopharma-closes-fourth-debenture-tranche-100-000-cancels/) A news release dated March 7, 2025, filed with the SEC in a 6-K in September 2026, reports a $100,000 debenture tranche and the swap of a director's warrants for options. It names no placement agent for the debentures. ## Latest Quantum Biopharma news 1. 2026-09-02 Listings [Quantum BioPharma applies to delist Class B shares from the CSE](https://aibio.space/news/quantum-biopharma-applies-delist-class-b-shares-cse/) Quantum BioPharma has applied to delist its Class B shares from the Canadian Securities Exchange, with September 4, 2026 expected as the last trading day, subject to approval. The company's own release does not give the trading volumes behind the decision. 2. 2026-03-27 Listings [Quantum Biopharma reports 2025 results, believes cash lasts past January 2028](https://aibio.space/news/quantum-biopharma-reports-2025-results-believes-cash-lasts-past/) Quantum BioPharma reports $11.3 million in cash and digital assets at the filing date and says cash lasts beyond January 2028. Its annual report shows year-end cash of $1.9 million, and the release does not split out the digital assets. ## Quantum Biopharma at a glance - **Ticker**: QNTM - **Listing**: NASDAQ - **Country**: Canada - **Cash, Dec 31, 2025**: $2.4 million ### Related companies - [IMV INC](https://aibio.space/companies/imv/) OTC: IMVIF - [Rapid Dose Therapeutics](https://aibio.space/companies/rapid-dose-therapeutics/) CSE: DOSE - [Microbix Biosystems](https://aibio.space/companies/microbix-biosystems/) TSX: MBX - [Aurinia Pharmaceuticals](https://aibio.space/companies/aurinia-pharmaceuticals/) NASDAQ: AUPH - [Onco-Innovations](https://aibio.space/companies/onco-innovations/) NEO: ONCO - [Cardiol Therapeutics](https://aibio.space/companies/cardiol-therapeutics/) TSX: CRDL - [DiagnaMed Holdings](https://aibio.space/companies/diagnamed/) CSE: DMED - [Medicenna Therapeutics](https://aibio.space/companies/medicenna-therapeutics/) TSX: MDNA ### Also on NASDAQ - [Iambic Therapeutics](https://aibio.space/companies/iambic-therapeutics/) IAM - [Prime Medicine](https://aibio.space/companies/prime-medicine/) PRME - [Bioventus](https://aibio.space/companies/bioventus/) BVS - [Puma Biotechnology](https://aibio.space/companies/puma-biotechnology/) PBYI - [Burning Rock Biotech](https://aibio.space/companies/burning-rock-biotech/) BNR - [Rockwell Medical](https://aibio.space/companies/rockwell-medical/) RMTI ## Quantum Biopharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$2.8 million](https://www.sec.gov/Archives/edgar/data/1771885/000118518526001069/) | [$6.1 million](https://www.sec.gov/Archives/edgar/data/1771885/000118518526001069/) | | Cash from operations | [-$8.2 million](https://www.sec.gov/Archives/edgar/data/1771885/000118518526001069/) | [-$6.9 million](https://www.sec.gov/Archives/edgar/data/1771885/000118518526001069/) | | Cash and equivalents | [$1.9 million](https://www.sec.gov/Archives/edgar/data/1771885/000118518526001069/) | [$6.0 million](https://www.sec.gov/Archives/edgar/data/1771885/000118518526001069/) | | Short-term investments | [$459,080](https://www.sec.gov/Archives/edgar/data/1771885/000118518526001069/) | [$1.2 million](https://www.sec.gov/Archives/edgar/data/1771885/000118518526001069/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $1.9 million, plus short-term investments of $459,080, $2.4 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Quantum Biopharma Was Quantum Biopharma delisted? Our latest story on this, dated Sep 2, 2026: "Quantum BioPharma applies to delist Class B shares from the CSE". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/quantum-biopharma-applies-delist-class-b-shares-cse/). What is the ticker symbol of Quantum Biopharma? Quantum Biopharma Ltd. trades under the ticker QNTM on NASDAQ. Where is Quantum Biopharma listed? Quantum Biopharma Ltd. is listed on NASDAQ. Our directory also records these other listings: GETTEX:0K91; LS:A2P8F1; LSX:A2P8F1. What is the SEC CIK of Quantum Biopharma? The SEC Central Index Key (CIK) for Quantum Biopharma Ltd. is 1771885. Its filings are on SEC EDGAR. How many shares does Quantum Biopharma have outstanding? 72 shares as of 2023-12-31, per the cover page of its 20-F filed 2025-03-28. Which country or territory is Quantum Biopharma listed under? Our directory records Quantum Biopharma Ltd. under Canada. What does Quantum Biopharma do? Our directory classifies Quantum Biopharma Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Quantum Biopharma? The ISIN recorded for Quantum Biopharma Ltd. is CA74764Y2050. Does aibio.space cover Quantum Biopharma? aibio.space lists Quantum Biopharma Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Quantum Biopharma incorporated? SEC records list its state or country of incorporation as A6. How much does Quantum Biopharma spend on research and development? $2.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Quantum Biopharma have? $2.4 million in cash and short-term investments at Dec 31, 2025, per its 20-F. What is the latest Quantum Biopharma (QNTM) stock news? Our latest story on Quantum Biopharma, dated Sep 17, 2026: "Quantum BioPharma closes fourth debenture tranche of $100,000, cancels director warrants". A news release dated March 7, 2025, filed with the SEC in a 6-K in September 2026, reports a $100,000 debenture tranche and the swap of a director's warrants for options. It names no placement agent for the debentures. [Source](https://aibio.space/news/quantum-biopharma-closes-fourth-debenture-tranche-100-000-cancels/). Does Quantum Biopharma have debt, a term loan or convertible notes? Our latest debt story, dated Sep 17, 2026: "Quantum BioPharma closes fourth debenture tranche of $100,000, cancels director warrants". A news release dated March 7, 2025, filed with the SEC in a 6-K in September 2026, reports a $100,000 debenture tranche and the swap of a director's warrants for options. It names no placement agent for the debentures. [Source](https://aibio.space/news/quantum-biopharma-closes-fourth-debenture-tranche-100-000-cancels/). How long will Quantum Biopharma's cash last? From our story of Mar 27, 2026: The release's headline also cites a "No Going Concern" status. [Source](https://aibio.space/news/quantum-biopharma-reports-2025-results-believes-cash-lasts-past/). ## Investor discussion: Quantum Biopharma Members talk about Quantum Biopharma (QNTM). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Quantum Biopharma, newest first. Each line links the filing it comes from. 1. 2026-10-08 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1771885/000117184326006529/exh_991.htm) 2. 2026-09-17 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1771885/000118518526004098/qntmex99-1.htm) 3. 2026-09-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1771885/000118518526003794/qntmex99-1.htm) 4. 2026-03-27 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1771885/000117184326001969/exh_991.htm) 5. 2025-12-22 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1771885/000117184325008046/exh_991.htm) 6. 2025-12-22 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1771885/000175392625001935/g085047_424b5.htm) 7. 2025-12-08 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1771885/000175392625001860/g085036_6k.htm) 8. 2025-11-07 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1771885/000117184325007124/exh_991.htm) 9. 2025-10-31 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1771885/000175392625001676/g084984_424b5.htm) 10. 2025-10-20 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1771885/000117184325006520/exh_991.htm) 11. 2025-07-22 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1771885/000117184325004594/exh_991.htm) 12. 2025-01-21 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1771885/000165495425000596/fsd_ex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:QNTM on TradingView](https://www.tradingview.com/symbols/NASDAQ-QNTM/). ## SEC filings and registration - **SEC name**: Quantum Biopharma Ltd. - **CIK**: 1771885 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: QNTM (Nasdaq) - **State or country of incorporation**: A6 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Emerging growth company - **Business address**: 1 ADELAIDE STREET EAST, SUITE 801, TORONTO, M5C 2V9 - **Phone**: (416) 854-8884 - **Shares outstanding**: 72 as of 2023-12-31 (20-F filed 2025-03-28) - **Former names**: FSD Pharma Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1771885/000117184326006529/f6k_100826.htm) filed 2026-10-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1771885/000117184326006429/f6k_100526.htm) filed 2026-10-06 - [6-K](https://www.sec.gov/Archives/edgar/data/1771885/000117184326006203/f6k_092426.htm) filed 2026-09-24 - [6-K](https://www.sec.gov/Archives/edgar/data/1771885/000118518526004098/qntm6k091726.htm) filed 2026-09-17 - [6-K](https://www.sec.gov/Archives/edgar/data/1771885/000117184326006084/f6k_091726.htm) filed 2026-09-17 - [6-K](https://www.sec.gov/Archives/edgar/data/1771885/000117184326006047/f6k_091426.htm) filed 2026-09-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1771885/000118518526003794/qntm6k090126.htm) filed 2026-09-02 - [6-K](https://www.sec.gov/Archives/edgar/data/1771885/000117184326005524/f6k_081426.htm) filed 2026-08-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001771885), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Quantum Biopharma Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker QNTM, recorded under Canada. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Quantum Biopharma Ltd. - **Ticker**: QNTM - **Listing**: NASDAQ - **Country or territory**: Canada - **Business scope**: Biotechnology - **ISIN**: CA74764Y2050 - **Other listed symbols**: GETTEX:0K91; LS:A2P8F1; LSX:A2P8F1 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-QNTM/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/quantum-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Quantum Biopharma (QNTM) news: delisting", 2026-10-31, https://aibio.space/companies/quantum-biopharma/